On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)The organization looks forward to the semiconductor industry in 2025: the AI replacement tide leads the growth, and the semiconductor ETF(512480) may usher in new development opportunities. On December 13, the semiconductor ETF(512480) closed down by 1.38%, with a turnover of 1.671 billion yuan. The constituent stocks are mixed, and Zhaoyi Innovation leads the rise. In terms of decline, SMIC led the decline. CICC said that after the boom in 2024, it is expected that the inventory of the semiconductor industry will stabilize and the relationship between supply and demand will be more balanced in 2025. With the gradual landing of AI cloud and end demand, domestic semiconductor elements will usher in new development opportunities. In addition, the AI-changing tide has a pulling effect on the downstream demand of the semiconductor design sector, which is expected to accelerate the growth of the semiconductor design sector in 2025 and inject new vitality into the industry.The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 394.6 billion yuan, that of Shenzhen Stock Exchange was 596.3 billion yuan, and that of Beizheng 50 was 11.1 billion yuan.
Weixing Co., Ltd.: Compared with the first half of the year, the growth rate of acquiring orders in the second half of the year gradually declined, but the overall growth rate still maintained. Weixing Co., Ltd. recently said in a conference call that due to the influence of the terminal consumption boom, downstream brand customers were cautious in placing orders, and the growth rate of acquiring orders in the second half of the year gradually declined compared with the first half of the year, but the overall growth rate still maintained. In recent years, the company has mainly focused on promoting globalization strategy, intelligent manufacturing strategy and improving manufacturing level, technical level and product quality, and achieved certain results.Li Dongsheng said that low-price competition has no way out, and it will only get involved. On December 11th, at TCL Global Innovation Conference, founder Li Dongsheng said that in the current market competition, low-price competition has no way out, and it will only get involved in endless "involution". To surpass its competitors, it is necessary to strive for more breakthroughs in high-end products. He Jun, vice president of TCL Industry, talked about the current development of industrial software enterprises in China in a subsequent interview. He also said that from the aspects of financing environment and market support for enterprises, China is not an environment where good software enterprises can be born at present, but in the long run, industrial software may make a breakthrough in China software, and this time will not be very fast, and it will not be seen for three or five years.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.
The yield of China's 30-year national debt "24 Special National Debt 06" fell below 2%, hitting a new low.The turnover of Shanghai and Shenzhen stock markets exceeded 1 trillion yuan for the 53rd consecutive trading day.Zuo Qiang served as the chairman and secretary of the Party Committee of China Construction No.1 Bureau (Group) Co., Ltd. On the afternoon of December 13th, China Construction No.1 Bureau (Group) Co., Ltd. held a meeting of cadres and workers. China Construction Group announced the decision to supplement the main leaders of China Construction No.1 Bureau (Group) Co., Ltd.: Comrade Zuo Qiang is the chairman and party secretary of China Construction No.1 Bureau (Group) Co., Ltd.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14